JP2001519813A - カルシウム溶解性化合物 - Google Patents

カルシウム溶解性化合物

Info

Publication number
JP2001519813A
JP2001519813A JP54292798A JP54292798A JP2001519813A JP 2001519813 A JP2001519813 A JP 2001519813A JP 54292798 A JP54292798 A JP 54292798A JP 54292798 A JP54292798 A JP 54292798A JP 2001519813 A JP2001519813 A JP 2001519813A
Authority
JP
Japan
Prior art keywords
disease
compound
calcium
compounds
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54292798A
Other languages
English (en)
Japanese (ja)
Inventor
バトナガー，プラディップ・クマー
ラゴ，アンパロ・エム
ヌグエン，トーマス・ティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2001519813A publication Critical patent/JP2001519813A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP54292798A 1997-04-04 1998-04-03 カルシウム溶解性化合物 Pending JP2001519813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4306297P 1997-04-04 1997-04-04
US60/043,062 1997-04-04
PCT/US1998/006618 WO1998044925A1 (fr) 1997-04-04 1998-04-03 Composes calcilytiques

Publications (1)

Publication Number Publication Date
JP2001519813A true JP2001519813A (ja) 2001-10-23

Family

ID=21925269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54292798A Pending JP2001519813A (ja) 1997-04-04 1998-04-03 カルシウム溶解性化合物

Country Status (4)

Country Link
EP (1) EP0998283A1 (fr)
JP (1) JP2001519813A (fr)
CA (1) CA2285556A1 (fr)
WO (1) WO1998044925A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025209A1 (fr) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd Derives de pyridinium destines au traitement de complications vasculaires liees au diabete et au vieillissement
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2002067851A2 (fr) * 2000-12-29 2002-09-06 Alteon, Inc. Procede de traitement ou d'amelioration de maladies fibreuses ou autres etats iiic
ES2243389T3 (es) * 2001-03-21 2005-12-01 Torrent Pharmaceuticals Ltd Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age.
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
WO2007132179A2 (fr) * 2006-05-15 2007-11-22 University Of Bath Agents thérapeutiques
WO2010045229A2 (fr) 2008-10-13 2010-04-22 University Of Rochester Protection et reparation de tissus mous cartilagineux et musculo-squelettiques
WO2010103429A1 (fr) 2009-03-10 2010-09-16 Pfizer Inc. Dérivés de l'acide 1,1-(diméthyl-éthylamino)-2-hydroxy-propoxy]-éthyl}-3-méthyl-biphényl-4-carboxylique utiles en tant qu'antagonistes des récepteurs du calcium
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze

Also Published As

Publication number Publication date
EP0998283A1 (fr) 2000-05-10
CA2285556A1 (fr) 1998-10-15
WO1998044925A1 (fr) 1998-10-15

Similar Documents

Publication Publication Date Title
JP4431609B2 (ja) 無機イオン活性化合物
US6221913B1 (en) Dialkyl ureas as calcitonin mimetics
US20070099938A1 (en) Antistress drug and medical use thereof
EP1070048B1 (fr) Composes calcilytiques
JP2003520850A (ja) 新規なメラノコルチン受容体作動薬および拮抗薬
US9458141B2 (en) Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
JP2014500882A (ja) カルシウム感知受容体活性化合物
JP2001519813A (ja) カルシウム溶解性化合物
US6335338B1 (en) Calcilytic compounds
JPS643185B2 (fr)
JP5113973B2 (ja) 新規のインドール誘導体および医薬としてのその使用
CN101511808A (zh) 二芳基醚衍生物及其用途
US6924295B2 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
TW200922584A (en) Organic compounds
JP2002536330A (ja) カルシウム消散化合物
TWI236469B (en) Diamine compound with condensed-ring groups
JP2007523076A (ja) カルシウム受容体アンタゴニスト化合物
US6291459B1 (en) Calcilytic compounds
US6864267B2 (en) Calcilytic compounds
DE60131781T2 (de) Kalzilytische verbindungen
US6239144B1 (en) Methods of treating bone loss
WO2006042007A2 (fr) Utilisation de composes de chromenone comme calcilytiques